Home・Lista de Ações・Vaxcyte Inc

Vaxcyte Inc

Fechado

SetorSaúde

57.96 0.1

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.55

Máximo

58.07

Indicadores-chave
By Trading Economics
Rendimento	-74M -321M
EPS	-2.3
Funcionários	507
EBITDA	-80M -315M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+96.88% upside

Dividendos
By Acuity
Próximos Ganhos	11 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-716M 7.7B
Abertura anterior	57.86
Fecho anterior	57.96

Sentimento de Notícias

By Acuity

50%

116 / 340 Ranking em Healthcare

Vaxcyte Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2026, 21:01 UTC

Vaxcyte Inc shares are lower in after-market hours, continuing a weak trading session without any specific news to explain the decline.

6 de ago. de 2026, 20:03 UTC

News

Vaxcyte reports a net loss of $284.3 million for Q2. Shares are trading higher as the company anticipates key Phase 3 trial data in 2027.

5 de ago. de 2026, 19:16 UTC

Vaxcyte Inc. shares are higher today, aligning with broader market trends, despite no specific news identified. The stock remains near its one-month range low.

4 de ago. de 2026, 20:21 UTC

Vaxcyte Inc. shares are lower in after-market trading, remaining flat since Tuesday's close and positioned below its 20-day moving average.

3 de ago. de 2026, 19:46 UTC

Vaxcyte Inc's shares are lower today, continuing a decline since Friday. The stock is trading near the lower end of its one-month range.

31 de jul. de 2026, 19:56 UTC

Correlated Moves

Shares lower amid broader sector sentiment; SPDR S&P Biotech ETF declines.

30 de jul. de 2026, 18:52 UTC

Vaxcyte Inc's shares are higher today amid strong buying activity, reaching an intraday high but remain below the 20-day moving average.

29 de jul. de 2026, 18:23 UTC

Vaxcyte Inc is lower in Wednesday's session, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

28 de jul. de 2026, 18:46 UTC

Vaxcyte Inc. shares are trading lower amid broader market trends and volatility, remaining below the 20-day moving average as bond yields decline.

27 de jul. de 2026, 19:46 UTC

Vaxcyte Inc shares are trading higher today, despite earlier declines and without specific company news. Broader market volatility is influenced by falling crude oil prices.

23 de jul. de 2026, 19:16 UTC

Vaxcyte Inc shares are lower today amid a broader decline in tech stocks following earnings reports from Alphabet and Tesla. No specific news was identified.

21 de jul. de 2026, 18:26 UTC

Vaxcyte Inc is trading higher today, continuing its advance since Monday's close. This movement occurs despite concerns over rising treasury yields and geopolitical tensions.

Comparação entre Pares

Variação de preço

Vaxcyte Inc Previsão

Preço-alvo

By TipRanks

96.88% parte superior

Previsão para 12 meses

Média 114.33 USD 96.88%

Máximo 163 USD

Mínimo 75 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Vaxcyte Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Vaxcyte Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

116 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.